Ferritin nanocage with intrinsically disordered proteins and affibody: A platform for tumor targeting with extended pharmacokinetics

Na Kyeong Lee, Eun Jung Lee, Soyoun Kim, Gi hoon Nam, Minwoo Kih, Yeonsun Hong, Cherlhyun Jeong, Yoosoo Yang, Youngro Byun, In-San Kim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Ferritin nanocages are of particular interest as a novel platform for drug and vaccine delivery, diagnosis, biomineralization scaffold and more, due to their perfect and complex symmetry, ideal physical properties, high biocompatibility, low toxicity profiles as well as easy manipulation by genetic or chemical strategies. However, a short half-life is still a hurdle for the translation of ferritin-based nanomedicines into the clinic. Here, we developed a series of rationally designed long circulating ferritin nanocages (LCFNs) with ‘Intrinsically Disordered Proteins (IDP)’ as a stealth layer for extending the half-life of ferritin nanocages. Through predictions with 3D modelling, the LCFNs were designed, generated and their pharmacokinetic parameters including half-life, clearance rate, mean residence time, and more, were evaluated by qualitative and quantitative analysis. LCFNs have a tenfold increased half-life and overall improved pharmacokinetic parameters compared to wild-type ferritin nanocages (wtFN), corresponding to the low binding against bone marrow-derived macrophages (BMDMs) and endothelial cells. Subsequently, a tumor targeting moiety, epidermal growth factor receptor (EGFR)-targeting affibody peptide, was fused to LCFNs for evaluating their potential as a theragnostic platform. The tumor targeting-LCFNs successfully accumulated to the tumor tissue, by efficient targeting via active and passive properties, and also the shielding effect of IDP in vivo. This strategy can be applied to other protein-based nanocages for further progressing their use in the field of nanomedicine.

Original languageEnglish
Pages (from-to)172-180
Number of pages9
JournalJournal of Controlled Release
Volume267
DOIs
Publication statusPublished - 2017 Dec 10

Fingerprint

Intrinsically Disordered Proteins
Ferritins
Pharmacokinetics
Neoplasms
Half-Life
Nanomedicine
Epidermal Growth Factor Receptor
Vaccines
Endothelial Cells
Macrophages

Keywords

  • Ferritin nanocages
  • Half-life
  • Intrinsically disordered protein
  • Nanomedicine
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Ferritin nanocage with intrinsically disordered proteins and affibody : A platform for tumor targeting with extended pharmacokinetics. / Lee, Na Kyeong; Lee, Eun Jung; Kim, Soyoun; Nam, Gi hoon; Kih, Minwoo; Hong, Yeonsun; Jeong, Cherlhyun; Yang, Yoosoo; Byun, Youngro; Kim, In-San.

In: Journal of Controlled Release, Vol. 267, 10.12.2017, p. 172-180.

Research output: Contribution to journalArticle

Lee, Na Kyeong ; Lee, Eun Jung ; Kim, Soyoun ; Nam, Gi hoon ; Kih, Minwoo ; Hong, Yeonsun ; Jeong, Cherlhyun ; Yang, Yoosoo ; Byun, Youngro ; Kim, In-San. / Ferritin nanocage with intrinsically disordered proteins and affibody : A platform for tumor targeting with extended pharmacokinetics. In: Journal of Controlled Release. 2017 ; Vol. 267. pp. 172-180.
@article{12f1c2f5a3354b8aa3b0d82cc59e9e2a,
title = "Ferritin nanocage with intrinsically disordered proteins and affibody: A platform for tumor targeting with extended pharmacokinetics",
abstract = "Ferritin nanocages are of particular interest as a novel platform for drug and vaccine delivery, diagnosis, biomineralization scaffold and more, due to their perfect and complex symmetry, ideal physical properties, high biocompatibility, low toxicity profiles as well as easy manipulation by genetic or chemical strategies. However, a short half-life is still a hurdle for the translation of ferritin-based nanomedicines into the clinic. Here, we developed a series of rationally designed long circulating ferritin nanocages (LCFNs) with ‘Intrinsically Disordered Proteins (IDP)’ as a stealth layer for extending the half-life of ferritin nanocages. Through predictions with 3D modelling, the LCFNs were designed, generated and their pharmacokinetic parameters including half-life, clearance rate, mean residence time, and more, were evaluated by qualitative and quantitative analysis. LCFNs have a tenfold increased half-life and overall improved pharmacokinetic parameters compared to wild-type ferritin nanocages (wtFN), corresponding to the low binding against bone marrow-derived macrophages (BMDMs) and endothelial cells. Subsequently, a tumor targeting moiety, epidermal growth factor receptor (EGFR)-targeting affibody peptide, was fused to LCFNs for evaluating their potential as a theragnostic platform. The tumor targeting-LCFNs successfully accumulated to the tumor tissue, by efficient targeting via active and passive properties, and also the shielding effect of IDP in vivo. This strategy can be applied to other protein-based nanocages for further progressing their use in the field of nanomedicine.",
keywords = "Ferritin nanocages, Half-life, Intrinsically disordered protein, Nanomedicine, Pharmacokinetics",
author = "Lee, {Na Kyeong} and Lee, {Eun Jung} and Soyoun Kim and Nam, {Gi hoon} and Minwoo Kih and Yeonsun Hong and Cherlhyun Jeong and Yoosoo Yang and Youngro Byun and In-San Kim",
year = "2017",
month = "12",
day = "10",
doi = "10.1016/j.jconrel.2017.08.014",
language = "English",
volume = "267",
pages = "172--180",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Ferritin nanocage with intrinsically disordered proteins and affibody

T2 - A platform for tumor targeting with extended pharmacokinetics

AU - Lee, Na Kyeong

AU - Lee, Eun Jung

AU - Kim, Soyoun

AU - Nam, Gi hoon

AU - Kih, Minwoo

AU - Hong, Yeonsun

AU - Jeong, Cherlhyun

AU - Yang, Yoosoo

AU - Byun, Youngro

AU - Kim, In-San

PY - 2017/12/10

Y1 - 2017/12/10

N2 - Ferritin nanocages are of particular interest as a novel platform for drug and vaccine delivery, diagnosis, biomineralization scaffold and more, due to their perfect and complex symmetry, ideal physical properties, high biocompatibility, low toxicity profiles as well as easy manipulation by genetic or chemical strategies. However, a short half-life is still a hurdle for the translation of ferritin-based nanomedicines into the clinic. Here, we developed a series of rationally designed long circulating ferritin nanocages (LCFNs) with ‘Intrinsically Disordered Proteins (IDP)’ as a stealth layer for extending the half-life of ferritin nanocages. Through predictions with 3D modelling, the LCFNs were designed, generated and their pharmacokinetic parameters including half-life, clearance rate, mean residence time, and more, were evaluated by qualitative and quantitative analysis. LCFNs have a tenfold increased half-life and overall improved pharmacokinetic parameters compared to wild-type ferritin nanocages (wtFN), corresponding to the low binding against bone marrow-derived macrophages (BMDMs) and endothelial cells. Subsequently, a tumor targeting moiety, epidermal growth factor receptor (EGFR)-targeting affibody peptide, was fused to LCFNs for evaluating their potential as a theragnostic platform. The tumor targeting-LCFNs successfully accumulated to the tumor tissue, by efficient targeting via active and passive properties, and also the shielding effect of IDP in vivo. This strategy can be applied to other protein-based nanocages for further progressing their use in the field of nanomedicine.

AB - Ferritin nanocages are of particular interest as a novel platform for drug and vaccine delivery, diagnosis, biomineralization scaffold and more, due to their perfect and complex symmetry, ideal physical properties, high biocompatibility, low toxicity profiles as well as easy manipulation by genetic or chemical strategies. However, a short half-life is still a hurdle for the translation of ferritin-based nanomedicines into the clinic. Here, we developed a series of rationally designed long circulating ferritin nanocages (LCFNs) with ‘Intrinsically Disordered Proteins (IDP)’ as a stealth layer for extending the half-life of ferritin nanocages. Through predictions with 3D modelling, the LCFNs were designed, generated and their pharmacokinetic parameters including half-life, clearance rate, mean residence time, and more, were evaluated by qualitative and quantitative analysis. LCFNs have a tenfold increased half-life and overall improved pharmacokinetic parameters compared to wild-type ferritin nanocages (wtFN), corresponding to the low binding against bone marrow-derived macrophages (BMDMs) and endothelial cells. Subsequently, a tumor targeting moiety, epidermal growth factor receptor (EGFR)-targeting affibody peptide, was fused to LCFNs for evaluating their potential as a theragnostic platform. The tumor targeting-LCFNs successfully accumulated to the tumor tissue, by efficient targeting via active and passive properties, and also the shielding effect of IDP in vivo. This strategy can be applied to other protein-based nanocages for further progressing their use in the field of nanomedicine.

KW - Ferritin nanocages

KW - Half-life

KW - Intrinsically disordered protein

KW - Nanomedicine

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=85028079317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028079317&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2017.08.014

DO - 10.1016/j.jconrel.2017.08.014

M3 - Article

C2 - 28821462

AN - SCOPUS:85028079317

VL - 267

SP - 172

EP - 180

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -